KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax: 2017-2018

Historic Long-Term Deferred Tax for Amneal Pharmaceuticals (AMRX) over the last 2 years, with Dec 2018 value amounting to $373.2 million.

  • Amneal Pharmaceuticals' Long-Term Deferred Tax rose 4.86% to $391.9 million in Q2 2019 from the same period last year, while for Jun 2019 it was $391.9 million, marking a year-over-year increase of 4.86%. This contributed to the annual value of $373.2 million for FY2018, which is 41454.45% up from last year.
  • According to the latest figures from FY2018, Amneal Pharmaceuticals' Long-Term Deferred Tax is $373.2 million, which was up 41,454.45% from $898,000 recorded in FY2017.
  • In the past 5 years, Amneal Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $373.2 million in FY2018 and a low of $898,000 during FY2017.
  • Moreover, its 2-year median value for Long-Term Deferred Tax was $187.0 million (2017), whereas its average is $187.0 million.
  • Data for Amneal Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY skyrocketed of 41,454.45% (in 2018) over the last 5 years.
  • Yearly analysis of 2 years shows Amneal Pharmaceuticals' Long-Term Deferred Tax stood at $898,000 in 2017, then surged by 41,454.45% to $373.2 million in 2018.